Hailshadow/iStock via Getty Images PTC Therapeutics ( NASDAQ: PTCT ) said the FDA has accepted its resubmitted New Drug Application for its drug Translarna, also known as ataluren, for the treatment of nonsense mutation Duchenne muscular dystrophy, or nmDMD. The company said the FDA has not provided.
Back to Health Page
